Ephraim Gardner

Ephraim Gardner

Auto-generated profile, based on publicly available information

Ephraim Gardner

University at Buffalo 1 Division of Hematology and Oncology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences Buffalo, New York

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2026 in Cancer Research
Verified
Journal Article
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
Reprogramming of the androgen receptor (AR) cistrome is associated with prostate cancer progression, and advanced castration-resistant prostate cancers (CRPC) tend to rely on reprogrammed/noncanonical AR signaling that remains active under treatment with AR signaling inhibitors (ARSI). In this study, we identified ecotropic viral integration site 1 (EVI1), an oncogenic nuclear transcription factor (TF) encoded by MECOM, as an AR-recruited coactivator of noncanonical signaling. In prostate cancer, MECOM was exclusively overexpressed in both CRPC and enzalutamide-resistant CRPC and interacted with AR in the nucleus. MECOM depletion in prostate cancer cells decreased proliferation, altered cell survival transcriptional programs, and reduced the number of super-enhancers (SE), leading to a dynamic change in the SE landscape and a decrease in the expression of SE-regulated oncogenic TFs, along with increased proapoptotic signatures. Notably, cells overexpressing MECOM and its protein, EVI1, were susceptible to PARP inhibitors (PARPi) regardless of their DNA damage response or homologous recombination repair (HRR) gene mutation status. These insights reveal the crucial role of EVI1 in regulating cell survival within the context of an AR-reprogrammed chromatin landscape. More importantly, the findings suggest that MECOM overexpression may be another biomarker that could significantly broaden the use of PARPis beyond those with HRR gene mutations. Significance: MECOM is a driver of androgen receptor inhibitor resistance in castrate-resistant prostate cancer that promotes susceptibility to PARP inhibition, positioning MECOM as a biomarker in patients without homologous recombination repair gene mutations.

17 June 2026
Verified
Other
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
Functional studies confers the role of MECOM in regulation of AR activity and survival transcriptional programs

17 June 2026
Verified
Other
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
MECOM expression increases with disease progression and treatment-resistance in PCa

17 June 2026
Verified
Other
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
Functional suppression of MECOM alters AR binding and H3K27ac enrichment in CRPC cell lines

17 June 2026
Verified
Other
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
PARP inhibitors in combination with enzalutamide suppress MECOM and AR expression, suppress proliferation, and increase apoptosis in enzalutamide-resistant CRPC

17 June 2026
Verified
Other
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
Ranking of Differential Expressed Transcription Factors Related to Figure 1C